Tumor Markers.

Slides:



Advertisements
Similar presentations
Dr. Amal S. Ahmed Ass Prof.Clinical Pathology Suez Canal University
Advertisements

TUMOR MARKERS Prof. Dr.Yıldız DİNÇER.
Tumor Markers Useful tool or part of the problem? Dr. Grant MacLean.
Tumor Markers Lecture one By Dr. Reem Sallam. Objectives  To briefly introduce cancers, their incidence, some common terms, and staging system.  To.
Bio 130 Human Biology Cancer Normal cells have regulation that keeps their rates of cell division in check. Normal cells generally remain in one location.
Doç.Dr. Jale Çoban Klinik Biyokimya Uzmanı
Tumor Markers Lecture one By Dr. Waheed Al-Harizi.
Genomics Lecture 7 By Ms. Shumaila Azam. Tumor Tumor – abnormal proliferation of cells that results from uncontrolled, abnormal cell division A tumor.
What is Cancer? How it occurs and cell cycle regulation.
Lecture 4. Special chemistry Definition Special Chemistry is a subsection of the Chemistry Laboratory of the Division of Clinical Pathology. This includes.
Biomarkers of ovarian cancer and cysts Reproductive Block 1 Lecture By: Reem Sallam, MD, MSc, PhD.
Eleni Galani Medical Oncologist
Tumor Markers: Clinical Usefulness
Tumor Markers By: dr. hassan el-banna.
2 years later, she noticed multiple cm
بسم الله الرحمن الرحيم.
Epidemiology of cancer:. Cancer incidence:  In males: Cancers of the lung, prostate, and colon are the leading causes of cancer deaths.  In females.
Cell Cycle and Cancer. Cancer Terms Neoplasm – new, abnormal growth of cells Benign – not cancerous Malignant - cancerous Cancer – cellular growth disorder.
EKUSILENI CLINICAL LABORATORY
SC430 Molecular Cell Biology
 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.
Tumor Markers.
Copyright © 2006 Pearson Education, Inc. publishing as Benjamin Cummings.
Tumor Biomarkers are high lightened Once Again Cancer Facts Cancer etiology Tumor Genetics Tumor MarkersLocation Classification Uses methods of detection.
Tumor Markers Lecture two By Dr. Reem Sallam. Objectives  To briefly enumerate the most commonly used methods to test for tumor markers  To describe.
Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012.
OF COLOREATAL CANCER USING SEROLOGIC TUMOR MARKERS DIAGNOSIS & MANAGEMENT.
Metastatic Cancer – Gross Pathology Lymph node - metastasis from breastLiver – metastasis from lung Vertebral column – metastasis from prostate Mesentery.
Human Biology Sylvia S. Mader Michael Windelspecht
Tumor markers Present; by Dr. Andalib Isfahan Medical School
Biochemical markers in disease diagnosis
بسم الله الرحمن الرحيم. Cancer Origin and Terminology Malignant Transformation of Cells Oncogenes and Cancer Induction Tumor Antigens Immune Responses.
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Tumormarkers.
Cancer Biology Tumour Markers Tumour Markers Prof. Kenneth Bagshawe FRS.
وما أوتيتم من العلم إلا قليلاً. Prepared by: Abdo A Elfiky.
Tumor Markers.
Regulating the Cell Cycle
Principles of Surgical Oncology Done by : 428 surgery team surgery team.
Male Reproductive System Kristine Krafts, M.D.. Male Reproductive System Outline Testis Prostate.
6/2/2016Naglaa Alhusseini1 TUMOR MARKERS Naglaa Fathy Alhusseini Ass.Prof. of Biochemistry and Molecular Biology
Tumor Markers American cancer society British Journal of Cancer By B.Heidari.
Chapter 6 Cancer. Frequency and Significance Cancer is the 2 nd leading cause of death in the United States Obviously, the term cancer covers many types.
VIII. CANCER = Uncontrolled Cell Division. Celebs with Cancer.
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
Biochemical markers for diagnosis of diseases and follow up Dr. Rana Hasanato Associate professor and consultant Head of clinical chemistry department.
Chapter 19 Tumor Markers Zou Xiong. DEFINITIONS-1 Tumor markers originally were defined as substances that can be measured quantitatively by immunochemical.
Lecture 11 Immunology Tumor immunology Dr: Dalia Galal.
Principles of Surgical Oncology
Biochemical markers for diagnosis and follow up of disease
Definition Signs & symptoms Treatment Root of the disease.
Unit 6: Tumor markers. Introduction… Cancer is the second leading cause of death in North America, accounting for > 2.7 million deaths annually Although.
Cancer Antigen 15-3 Alison Nolan DT204/2. What is Cancer?  Cancer is a disease which is characterized by uncontrolled proliferation of cells.  This.
ABIRA KHAN TUMOR MARKERS & CANCER TREATMENT. TUMOR MARKERS Biological substances synthesized and released by cancer cells or produced by the host in response.
Tumor markers Definition Cancer Carcinogenic agents, Endocrine factors Oncogenic viruses, and Ionizing radiation Metastasis Main tumor markers CEA, AFP,
INTRODUCTION & OBJECTIVES Introduction: The carcinogenesis of hepatocellular carcinoma (HCC) is a multifactorial, multistep and complex process. Its prognosis.
Chapter 7 Neoplasia.
Aim: How can mitosis lead to a disruption in homeostasis?
Common pitfall in Oncology Luangyot Thongthieang, MD MEDICAL ONCOLOGY UNIT INTERNAL MEDICINE, KHONKAEN HOSPITAL.
Tumor markers 1111.
SURGICAL ONCOLOGY AND TUMOR MARKERS
What is it? How is it treated? What makes a person susceptible to it?
GENETIC BIOMARKERS.
Male Reproductive System
Cyclins, Mutagens and Oncogenes
Aim # 51: How can mitosis lead to a
Tumor Marker Tests.
ד"ר שרית בר ששת בי"ח בילינסון
Objectives: 1. Cancer and the cell cycle checkpoints, reqmts to advance oncogenes tumor suppressor genes 2. 6 Traits of cancerous cells 3. Facts on.
Hormonal Control of Pregnancy and Lactation
Presentation transcript:

Tumor Markers

Tumor Tumor refers to the uncontrolled growth of cells that can develop into a solid mass and spread to other areas of the body Although it is often specified as a single disorder, cancer is a broad term used to describe more than 200 different diseases that affect more than 50 tissues It is important to understand that not all tumors are cancerous. There are benign tumors where the growth is limited to certain part of the body. A tumor becomes cancer when it is malignant.

Tumor The formation (tumorigenesis) and spreading (metastasis) of tumors are caused by a complex combination of inherited and acquired genetic mutations During tumorigenesis, these mutations include: activation of growth factors (e.g., epidermal growth factor [EGF]) and oncogenes (e.g., K-ras), in combination with inhibition of apoptosis, tumor suppressor, and cell cycle regulation genes (e.g., BRCA1, p53, cyclins) As cancer progresses toward metastasis, additional genetic changes are required such as: loss of cell adhesion proteins (e.g., Beta-catenin and E-cadherin) and activation of angiogenesis genes (e.g., VEGF)

Stages of Tumor Cancer severity is generally classified by a combination of several factors. Depending on the type of cancer, these factors include tumor size, histology, regional lymph node involvement, and presence of metastasis. For most solid tumors (e.g., breast, lung, kidney), cancer is broadly classified (using roman numerals I–IV) into four stages

Tumor Markers A Tumor marker is a biological substance synthesized and released by: The tumor or by the host in response to tumor tissue It may be used to: Detect the presence of a tumor Monitor the progress of disease Monitor the response to treatment

Tumor Antigens Tumor specific antigens Tumor associated antigens Direct product of oncogenesis Disorganization of the genetic information leading to synthesis of antigens that are unique to the specific tumor cell Tumor associated antigens Most antigens are not specific for individual tumors but rather are usually associated with different tumors derived from the same or closely related tissue E.g. Oncofetal antigens: Antigens present in normal fetal growth and stimulated by malignancies later in life

How to identify tumor marker ? On cell Immunocytochemistry, Flow cytometry On tissue Immunohistochemistry In body fluids Blood, urine, CSF, Amniotic fluid RIA, EIA

Tumor markers in Cancer Management Screening Diagnosis Staging & Prognosis Therapy Monitoring Detecting recurrence

Tumor markers in Cancer Management

Screening Tumor markers play a limited role for tumor screening, because relatively low sensitivity lack of specificity Inappropriate for the detection of small in situ cancer However, successful cancer screening has been carried out by measuring tumor markers Eg. PSA → prostate cancer Carcinoma in situ is, by definition, a localized phenomenon, with no potential for metastasis unless it progresses into cancer.

Screening Susceptibility to cancer can be determined using molecular diagnostics in patients with breast, ovarian, or colon cancer Screening for susceptibility to breast and ovarian cancers is done by: identifying germline BRCA1 and BRCA2 mutations. Similarly, familial colon cancers can be identified by: the presence of the adenomatous polyposis coli gene (APC)

Diagnosis Tumor marker is not the key diagnostic examination, but can be a complementary sign to clinical finding or medical imaging AFP → hepatoma

Staging & Prognosis The major clinical value of tumor markers is in tumor staging, monitoring therapeutic response and detecting recurrence The tumor markers and medical imaging are complementary in the pre-therapeutic and post-therapeutic staging

Staging & Prognosis Serum concentration of tumor markers increases with tumor progression and usually reaches the highest levels when tumors become metastasized. The serum levels of tumor markers at diagnosis are likely to reflect the aggressiveness of the tumor and help predict the outcome for the patients. High levels indicate the presence of a malignant or metastatic tumor → poor prognosis.

Monitoring and Disease Recurrence One of the most useful applications of tumor markers is monitoring therapy efficacy and detecting disease recurrence. After surgical resection, radiation, or drug therapy of cancer (chemotherapy), tumor markers are routinely followed. In patients with elevated tumor markers at diagnosis, effective therapy results in a dramatic decrease or disappearance of the tumor marker.

Monitoring and Disease Recurrence If the initial treatment is effective, the appearance of circulating tumor markers can then be used as a highly sensitive marker of recurrence Many markers have a significant lead time of several months before disease would be detected by other methods, allowing treatment of an earlier-stage cancer.

Ideal Tumor Marker Characteristics Sensitive & Specific Presence of a given marker identifies an exact malignancy Concentration proportional to tumor size Concentration changes with growth or reduction of malignancy Concentration is low after remission Concentration is a good indicator of prognosis Short half-life (concentration reflects current conditions)

Reality of tumor markers Unfortunately, most tumor markers only possess some of the ideal characteristics (never all of them) Most tumor markers are not very sensitive and are poor screening tests for the detection of malignancies Most tumor markers are best utilized to confirm or monitor already diagnosed cancers ability to correctly identify people who have the disease

Different Types of Tumor Markers Fetal antigens Proteins Hormones Enzymes Steroid Receptors

Oncofetal antigens Oncofetal antigens expressed transiently during normal fetal development and are then turned on again in the formation tumors

CEA (Carcinoembryonic Antigen ) Oncofetal antigen Best tumor marker for monitoring of colon cancer Also elevated in Smokers, Alcoholic cirrhosis & Ulcerative colitis Good correlation with treatment and prognosis of colon cancer ↓ CEA after surgical removal of tumor ↑ CEA if malignancy re-occurs or metastasizes Levels correlate well with chemotherapy and irradiation treatment Assay: ELISA and RIA

Alpha –FetoProtein (AFP) Oncofetal antigen ↑ in pregnancy and certain malignancies Useful tumor marker for monitoring Liver cancer, hepatocellular carcinomas (HCC) Gonadal malignancies Serial measurements of AFP used to monitor treatment and post-surgery in patients with HCC. Assay: ELISA and RIA

Prostate Specific Antigen (PSA) PSA is a tissue specific protein secreted by malignant prostate cells PSA is present in low concentrations of normal males, but elevated in malignancies and other conditions Good screening test for the detection of prostate cancer in older males and the monitoring of previously diagnosed tumors Complete removal of prostate should result in an undetectable total PSA in serum, any measurable tPSA would indicate residual prostatic tissue or metastasis. Assay: Immunoassays (ELISA) Total (t) PSA = free (f) PSA + complex (c) PSA

CA 125 CA 125 is a protein that is associated with normal ductal tissue Utilized to evaluate gonadal ovarian cancers CA125 is not efficient in detecting early (more treatable) ovarian cancers CA125 is useful in detecting late ovarian cancers and recurrence of cancers False positives may occur, resulting in unnecessary treatment 75 % of ovarian cancers are not diagnosed until late in the disease. Assay: ELISA , RIA

Paraproteins Any of the incomplete monoclonal immunoglobulins that occur in plasma cell disorders Paraproteins are detectable in either serum or urine in 98-99% of patients with Multiple Myeloma. Their detection is valuable in the diagnosis of this condition Paraprotein concentrations correlate well with Tumor bulk Reduction in the amount of paraprotein is a good indicator of the efficacy of treatment.

Hormones as tumor markers hCG is a hormone produced by the normal placenta (pregnancy) The presence of hCG in the plasma at other times indicates the presence of abnormal trophoblastic tissue tumors of the ovary and testis. The outermost layer of cells of the mammalian blastocyst that attaches the fertilized ovum to the uterine wall and serves as a nutritive pathway for the embryo. It is a prognostic indicator for ovarian cancer, a diagnostic marker for classification of testicular cancer Assay: ELISA Human Chorionic Gonadotropin

Enzymes as Tumor Markers Plasma enzyme activities are often increased in patients with cancer, usually a secondary effect of the tumor rather than a result of secretion of an enzyme by the tumor. Examples include the increase in alkaline phosphatase activity seen in patients with bone cancer. Increase in the plasma activity of the placental type in plasma occurs in many patients with lung, ovarian & others Measurement of placental alkaline phosphatase is of value in monitoring the response of such patients to treatment.

Steroid Receptors Hormonally dependent organs (breast) give rise to malignancies that may in themselves be hormonally dependent Eliminating hormonal stimulation by drugs leads to a regression of the respective malignancy Predicting which tumor respond to hormonal manipulation can be achieved by measuring steroid hormone receptors on tumors

Estrogen & Progesterone Receptors It is a protein localized in the nuclei of mammary and uterine tissue. Patients whose primary tumors demonstrated ER will respond to hormone therapy. ER and progesterone receptor assays are used to predict the therapeutic response of breast cancer patients to hormonal treatment